deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 4-arm NCT03441113

Extended Access of Momelotinib in Adults With Myelofibrosis

Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Sponsor: GlaxoSmithKline

Conditions Neoplasms Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) Post-polycythemia Vera Myelofibrosis (Post-PV MF) Primary Myelofibrosis (PMF)
Interventions MMB
Updated 33 times since 2018 Last updated: May 15, 2024 Started: May 3, 2018 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03441113, this PHASE2 trial focuses on Neoplasms and Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) and remains ongoing. Sponsored by GlaxoSmithKline, it has been updated 33 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jan 2020 · 7 months · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Apr 2023 · 3 months · monthly snapshot~Apr 2023 – ~Jul 2023 · 3 months · monthly snapshot~Jul 2023 – ~Jun 2024 · 11 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

33 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2023 — Jun 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 28 earlier versions

  1. Apr 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Enrolling By Invitation → Active Not Recruiting

  2. Jan 2023 — Apr 2023 [monthly]

    Enrolling By Invitation PHASE2

  3. Sep 2022 — Jan 2023 [monthly]

    Enrolling By Invitation PHASE2

  4. Jul 2022 — Sep 2022 [monthly]

    Enrolling By Invitation PHASE2

  5. Jun 2022 — Jul 2022 [monthly]

    Enrolling By Invitation PHASE2

  6. May 2022 — Jun 2022 [monthly]

    Enrolling By Invitation PHASE2

  7. Apr 2022 — May 2022 [monthly]

    Enrolling By Invitation PHASE2

  8. Mar 2022 — Apr 2022 [monthly]

    Enrolling By Invitation PHASE2

  9. Feb 2022 — Mar 2022 [monthly]

    Enrolling By Invitation PHASE2

  10. Dec 2021 — Feb 2022 [monthly]

    Enrolling By Invitation PHASE2

  11. Nov 2021 — Dec 2021 [monthly]

    Enrolling By Invitation PHASE2

  12. Oct 2021 — Nov 2021 [monthly]

    Enrolling By Invitation PHASE2

  13. Sep 2021 — Oct 2021 [monthly]

    Enrolling By Invitation PHASE2

  14. May 2021 — Sep 2021 [monthly]

    Enrolling By Invitation PHASE2

  15. Jan 2021 — May 2021 [monthly]

    Enrolling By Invitation PHASE2

  16. Mar 2020 — Jan 2021 [monthly]

    Enrolling By Invitation PHASE2

  17. Jan 2020 — Mar 2020 [monthly]

    Enrolling By Invitation PHASE2

  18. Jun 2019 — Jan 2020 [monthly]

    Enrolling By Invitation PHASE2

  19. May 2019 — Jun 2019 [monthly]

    Enrolling By Invitation PHASE2

  20. Mar 2019 — May 2019 [monthly]

    Enrolling By Invitation PHASE2

  21. Jan 2019 — Mar 2019 [monthly]

    Enrolling By Invitation PHASE2

  22. Dec 2018 — Jan 2019 [monthly]

    Enrolling By Invitation PHASE2

  23. Oct 2018 — Dec 2018 [monthly]

    Enrolling By Invitation PHASE2

  24. Sep 2018 — Oct 2018 [monthly]

    Enrolling By Invitation PHASE2

  25. Aug 2018 — Sep 2018 [monthly]

    Enrolling By Invitation PHASE2

  26. Jul 2018 — Aug 2018 [monthly]

    Enrolling By Invitation PHASE2

  27. Jun 2018 — Jul 2018 [monthly]

    Enrolling By Invitation PHASE2

    Status: Not Yet Recruiting → Enrolling By Invitation

  28. Mar 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Aalborg, Denmark , Adelaide, Australia , Afula, Israel , Airdrie, United Kingdom , Antwerp, Belgium , Ashkelon, Israel , Ashkelton, Israel , Atlanta, United States , Aurora, United States and 101 more locations